Viridian Therapeutics Balance Sheet
NASDAQ: VRDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viridian Therapeutics financial position
At the end of fiscal 2025, Viridian Therapeutics reported total assets of $899.4 million, up 21.1% from a year earlier against total liabilities of $177.3 million. Shareholders' equity stood at $722.2 million, or 80.3% of assets. The company held $212.4 million in cash and equivalents against $34.2 million of debt, a net cash position of $178.1 million.
The current ratio (current assets divided by current liabilities) was 12.65, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.05.
Summary generated from market data by MetaCap's automated system. Methodology
Viridian Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 212.38M | 99.59M | 102.83M | 155.58M | 42.30M | 45.90M | 24.85M | 32.61M | 47.44M | 22.10M |
| Short-Term Investments | 662.27M | 617.99M | 374.54M | 268.97M | 154.67M | 81.74M | 2.00M | 29.88M | 0 | — |
| Receivables | — | — | — | — | — | — | 108.00K | 24.00K | 1.46M | 20.00K |
| Inventory | — | — | — | — | — | — | — | — | — | 64.00K |
| Total Current Assets | 894.23M | 738.46M | 486.48M | 431.17M | 200.16M | 129.61M | 29.74M | 65.37M | 51.87M | 23.88M |
| Property, Plant & Equipment | 1.23M | 1.24M | 1.67M | 1.33M | 375.00K | 309.00K | 523.00K | 727.00K | 563.00K | 625.00K |
| Intangible Assets | 0 | — | — | — | — | — | — | — | — | — |
| Long-Term Investments | — | — | — | — | — | — | 0 | — | — | — |
| Total Assets | 899.42M | 742.40M | 490.42M | 435.09M | 203.71M | 131.25M | 30.26M | 66.15M | 52.48M | 24.76M |
| Accounts Payable | 8.68M | 2.14M | 2.24M | 14.23M | 2.33M | 670.00K | 1.10M | 571.00K | 906.00K | 1.01M |
| Short-Term Debt | — | 0 | 0 | — | — | — | — | — | — | — |
| Total Current Liabilities | 70.70M | 47.87M | 26.64M | 33.35M | 13.64M | 10.67M | 10.18M | 6.73M | 3.90M | 6.88M |
| Long-Term Debt | 34.24M | 20.58M | 20.20M | 4.64M | 0 | 0 | 4.33M | 8.00M | 9.92M | 2.82M |
| Total Liabilities | 177.25M | 70.76M | 48.40M | 40.03M | 15.99M | 11.22M | 14.51M | 14.80M | 13.97M | 9.71M |
| Shareholders' Equity | 722.17M | 671.64M | 442.02M | 395.06M | 187.72M | 120.04M | 15.75M | 51.34M | 38.51M | -61.92M |
| Retained Earnings | -1.34B | -995.86M | -725.91M | -488.17M | -358.30M | -278.89M | -168.17M | -126.30M | -93.59M | -67.08M |
| Total Debt | 34.24M | 20.58M | 20.20M | 4.64M | 0 | 0 | 4.33M | 8.00M | 9.92M | 2.82M |
| Net Cash (Debt) | 840.41M | 697.00M | 457.17M | 419.90M | 196.97M | 127.64M | 22.52M | 54.48M | 37.52M | 19.28M |
| Shares Outstanding | 101.83M | 80.99M | 53.99M | 41.31M | 23.92M | 4.23M | 2.32M | 30.84M | 22.57M | 833.74K |
This table shows 10 annual periods of Viridian Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow VRDN's reporting calendar. What is a balance sheet?